Originally published by Robert Kraft.
Bloomberg News reports that the Centers for Medicare and Medicaid Services said that Mylan NV has “for years overcharged the U.S. Medicaid health program to buy its EpiPen shot…despite being told that it needed to give bigger discounts under the law.” According to a letter from the CMS, Medicaid “spent about $797 million on EpiPens” from 2011 to 2015, which “included rebates of about 13 percent.” However, the US should have received a rebate of at least 23.1 percent.
From the news release of the American Association for Justice.
Curated by Texas Bar Today. Follow us on Twitter @texasbartoday.
from Texas Bar Today http://ift.tt/2itf49M
via Abogado Aly Website
No comments:
Post a Comment